What is the recommended management for normal tension glaucoma?

Management of Normal Tension Glaucoma

IOP reduction remains the cornerstone of normal tension glaucoma management, with a target of 30% reduction from baseline (typically to 12-14 mmHg), despite IOP being in the statistically normal range. 1

Initial Treatment Approach

First-Line Medical Therapy

• Prostaglandin analogues are the preferred initial medication (88% of ophthalmologists choose this as first-line) 2
• Alternative: Brimonidine (10% of ophthalmologists) 2
• Target IOP reduction: 30% from baseline levels 1

The evidence strongly supports aggressive treatment even without documented progression. 70% of ophthalmologists initiate treatment in mild-to-moderate NTG without waiting for documented disease progression 2, which is more aggressive than older trial protocols but reflects contemporary understanding of the disease.

Treatment Algorithm

Step 1: Establish baseline and target IOP

• Measure IOP at multiple visits to establish true baseline
• Set target at 30% reduction (typically 12-14 mmHg) 1
• Document optic nerve appearance and visual fields

Step 2: Initiate prostaglandin analogue

• Most efficacious and well-tolerated class 3
• Once-daily dosing improves adherence
• Avoid nighttime beta-blocker dosing (associated with nocturnal BP reduction and potential progression) 3

Step 3: Add or switch if target not met

• Add brimonidine as second agent 1
• Consider topical carbonic anhydrase inhibitors
• Avoid beta-blockers at night 3

Step 4: Consider laser trabeculoplasty

• Selective laser trabeculoplasty (SLT) when medications fail, adherence is poor, or cost/side effects are prohibitive 4, 5
• Can reduce medication burden in 75% of cases 4

Step 5: Surgical intervention for refractory cases

• Trabeculectomy when medical/laser therapy insufficient 1
• Target remains 30% IOP reduction

Critical Risk Factors Requiring More Aggressive Treatment

High-risk features demanding earlier/more aggressive intervention:

• Family history of glaucoma 6
• Mean IOP >14.2 mmHg (significant breakpoint for faster RNFL thinning) 6
• Maximum IOP spikes during follow-up 6
• Disc hemorrhages 4
• Thin central corneal thickness 4

Important caveat: Recent evidence shows that no patients with mean IOP <11 mmHg demonstrated progression 6, suggesting this may be a safe lower threshold in myopic NTG patients.

Beyond IOP: Vascular Risk Factor Management

While IOP reduction is the only proven modifiable factor, NTG likely represents part of a small vessel disease spectrum 7. Consider:

• Systemic calcium channel blockers (nifedipine) for vascular perfusion 1
• 24-hour blood pressure monitoring to identify nocturnal hypotension 1
• Avoid over-treatment of systemic hypertension 1
• Address Raynaud's phenomenon, migraine, and vascular risk factors 1

Monitoring Strategy

Follow-up intervals based on disease severity:

• Measure IOP at each visit
• Visual field testing every 6-12 months 6
• OCT RNFL thickness every 6-12 months 6
• Optic nerve photography for comparison

If progression occurs despite treatment:

• Lower target IOP further (additional 20-30% reduction) 5
• Reassess for secondary causes of optic neuropathy 5
• Consider surgical intervention 1

Common Pitfalls to Avoid

1. Waiting for documented progression before treating moderate disease - Contemporary practice favors earlier intervention 2
2. Using nighttime beta-blockers - Associated with nocturnal BP drops and potential progression 3
3. Accepting 20% IOP reduction as adequate - NTG requires 30% reduction 1
4. Ignoring vascular risk factors - These may be modifiable contributors 7, 1
5. Assuming all "normal" IOPs are safe - Patients with mean IOP >14 mmHg remain at risk 6

The management paradigm has shifted toward more aggressive early treatment based on risk stratification rather than waiting for documented progression, reflecting the understanding that IOP reduction prevents visual disability even when pressures start in the "normal" range 8.